



**2021 - EBF Cyberconnect Events:**  
**Focus Workshop: Spotlight on (LBA/CBA & Automation) TECHNOLOGY**  
**20-21 May 2021**

**Day 1 (times are CEST)**

<b>12:30</b>	<b>12:45</b>	<b>Coming online</b>
<b>12:45</b>	<b>13:00</b>	<b>Getting started - Welcome</b> Philip Timmerman - EBF
<b>13:00</b>	<b>14:30</b>	<b>Session 1: Ligand binding assay technological innovation</b>
13:00	13:10	Introduction to the session by the session chair (Robert Nelson, Covance)
13:10	13:30	Gregor Jordan, F. Hoffmann La Roche <i>Experience in the use of S-PX imaging and analysis system for sensitive target engagement analysis</i>
13:30	13:50	Christoph Bock, Abbvie <i>Development of a high sensitivity, single-molecule based ligand binding assay for the detection of biomolecules in a regulated bioanalysis lab – Opportunities, Challenges and Limitations</i>
13:50	14:10	John Chappell, Gyros <i>Determining Binding Affinity and Kinetics using solution based Ligand binding</i>
14:10	14:30	Q&A <i>Including introduction to session 2 and the round tables</i>
<b>15:00</b>	<b>16:50</b>	<b>Session 2: Functional assays becoming ready for the toolbox of the regulated BA lab</b>
15:00	15:10	SHORT recap of introduction into the session 2 & round tables by session chair (Anna Laurén, Novo Nordisk)
15:10	15:30	Henko Tadema, PRA-HS <i>Flow cytometry: The pivotal use of flow cytometry in cell therapy development</i>
15:30	15:50	Sion Lewis, UCB Pharma <i>Flow cytometry: Evolution of the flow lab into the Bioanalytical world</i>
15:50	16:10	Julian J. Freen-van Heeren, Sanquin <i>Proof of principle for the use of the T cell ELISpot in clinical trial settings</i>
16:10	16:30	Chiara Cazzin, on behalf of EBF <i>Considerations for the context of use of qPCR application and validation in the BA laboratory"</i>
16:30	16:50	Jessica Zheng Wang, AstraZeneca <i>Development of a mechanism of action reflective and robust potency assay for a therapeutic antibody against alpha toxin using rabbit erythrocytes</i>
<b>16:50</b>	<b>17:00</b>	<b>Logistic break</b> - break into small e-tables/rooms for Interactive round table
<b>17:00</b>	<b>18:15</b>	<b>Session 2: Interactive round tables</b> <i>Theme: Who will grab "session-2 technologies"? and what makes sense or doesn't from a regulatory perspective....</i> <i>Outcome will be presented on day 2 and is input for the closing panel discussion</i>
<b>18:15</b>		Close breakout rooms <i>End of day 1 in plenary "see you tomorrow"</i> <i>Zoom session stays open to allow continued session or 1/1 interactions</i>
<b>19:00</b>		<b>Zoom closes</b>

## Day 2 (times are CEST)

12:45	13:00	<b>Coming online</b>
13:00	14:40	<b>Session 3: Business Strategies driving Automation or Automation driving Business Strategies?</b> Session chair: Johannes Stanta, Freeline Therapeutics
13:00	13:20	Johannes Stanta, on behalf of the EBF (and session chair) <i>Blue Sky</i>
13:20	13:40	John Smeraglia, UCB Pharma <i>Role of automation in maximizing portfolio value – the future is now.</i>
13:40	14:00	Nils Boehm, Abbvie <i>Automation: Impact on operational workflows and information management</i>
14:00	14:20	Katharina Lang, Novo Nordisk <i>Fully paperless or less paper? A journey towards the paperless lab</i>
14:20	14:40	Cecilia Arfvidsson, on behalf of the EBF <i>Automation and the DI challenges</i>
14:40	15:00	<b>Break</b>
15:00	16:40	<b>Session 4 - Overcoming challenges - Automation solutions delivering value (incl. pandemic inspired solutions)</b> Session chair: Matthew Barfield, F. Hoffmann - La Roche
15:00	15:20	Animesh Shukla, AstraZeneca <i>Benefits, Challenges and Solutions for Setting up Automation in a Regulated Lab: A Case Study</i>
15:20	15:40	Scott Summerfield, GlaxoSmithKline <i>Transitioning to an 'automation-first' culture in Bioanalysis – our learnings from the last 3 year</i>
15:40	16:00	Steffan Svejgaard Petersen, Novo Nordisk <i>How high-throughput COVID-19 analysis can shape the future of our laboratory automation</i>
16:00	16:20	Michael Gröschl, Celerion <i>Lab automation in pandemic times – how can robots ensure lab staff's health and safety?</i>
16:20	16:40	Q&A and discussion
16:40	17:00	<b>Short break</b>
17:00	18:00	<b>Session 2 round table recap and close out panel discussion</b> <i>Feedback from day-1 round table</i> <i>Panel discussion and recommended next steps</i>
18:00		<b>Adjourn</b> <i>Meeting ends</i> <i>Zoom session stays open to allow continued session or 1/1 interactions</i>
19:00		<b>Zoom closes</b>



Organising Committee: : Matthew Barfield (Roche), Anna Laurén (NovoNordisk), Robert Nelson (Covance), Johannes Stanta (Freeline Therapeutics) and Philip Timmerman (EBF)